Showing 931-940 of 1868 results for "".
- From AAD: What's New in Acne and Rosacea?https://practicaldermatology.com/news/from-aad-whats-new-in-acne-and-rosacea/2471565/Dermatologists gathered for the Acne and Rosacea session at the 2025 American Academy of Dermatology in Orlando conference were treated to comprehensive updates on two prevalent skin conditions—acne and rosacea—presented by Julie Harper, MD, and Hilary Baldwin, MD,
- Research Letter: Molecule Enhances Skin Barrier, Reduces Retinoid Side Effectshttps://practicaldermatology.com/news/research-letter-molecule-enhances-skin-barrier-reduces-retinoid-side-effects/2471610/A formulation containing Epicutis Skincare’s proprietary TSC molecule significantly reduced erythema and dryness caused by tretinoin, according to a research letter published in the Journal of Cosmetic Dermatology.
- Incoming AAD President Dr. Taylor Pledges to 'Take Care of Dermatologists'https://practicaldermatology.com/news/Incoming-AAD-President-Dr-Taylor-Pledges-Take-Care-Dermatologists/2471549/The theme of the next American Academy of Dermatology (AAD) presidency will be taking care of dermatologists so that they can take care of their patients, incoming president Susan C. Taylor, MD, FAAD, said in an address at the 2025 AAD Annual Meeting in Orlando, Florida. “Just as we treat
- Martha Stewart Describes Neurotoxin Preferenceshttps://practicaldermatology.com/news/martha-stewart-describes-neurotoxin-preferences/2471541/BOTOX Cosmetic’s platysma bands indication has a fan in Martha Stewart. The keynote speaker at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, said she visits her dermatologist “once every couple months.” Gesturing to her jaw and neck, Stewart said she ge
- Positive Results Reported From Delgocitinib CHE Trial in Chinahttps://practicaldermatology.com/news/Positive-Results-Reported-Delgocitinib-CHE-Trial-China/2471379/Positive results were announced for the primary endpoint from the double-blind treatment period of the DELTA China phase 3 clinical trial with Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of Chinese adults and adolescents (aged 12 a
- Study: Mohs Lowers Local Recurrence in Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/study-mohs-lowers-local-recurrence-in-cutaneous-squamous-cell-carcinoma/2471328/New research published in JAMA Dermatology suggested that Mohs micrographic surgery (MMS) was associated with a lower local recurrence rate for high-stage cutaneous squamous cell carcinoma (cSCC). The retrospective coho
- Dr. Lain Discusses Predictive Modeling for PsO Biologic Selectionhttps://practicaldermatology.com/news/Dr-Lain-Discusses-Predictive-Modeling-PsO-Biologic-Selection/2471252/Edward (Ted) Lain, MD, MBA, reminded attendees at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, that a method exists for selecting the best class of biologic for each psoriasis patient. “I just want to keep this in the public conscience here,” Dr. Lain said. “There i
- Care Urged for Adult-Onset AD Diagnoseshttps://practicaldermatology.com/news/Care-Urged-Adult-Onset-AD-Diagnoses/2471216/As revolutionary as the latest approved therapeutics for atopic dermatitis have been, Daniela Kroshinsky, MD, MPH, cautioned that dermatologists must be vigilant and consider biopsies for atypical or nonresponsive cases before starting dupilumab or a JAK inhibitor. Speaking at the Winter C
- Surgical Excision Outperforms Curettage Plus Imiquimod for nBCChttps://practicaldermatology.com/news/surgical-excision-outperforms-curettage-plus-imiquimod-for-nbcc/2471123/Surgical excision (SE) is significantly more effective than superficial curettage (SC) followed by imiquimod cream, 5%, in maintaining tumor-free survival for nodular basal cell carcinoma (nBCC) after five years, according to a new analysis in JAMA Dermatology.
- Football Star OBJ to Raise Awareness of Seborrheic Dermatitis With Arcutishttps://practicaldermatology.com/news/Football-Star-OBJ-Raise-Awareness-Seborrheic-Dermatitis-With-Arcutis/2471099/NFL star Odell Beckham Jr. will help raise awareness of seborrheic dermatitis as part of a partnership with Arcutis Biotherapeutics, the company announced. “Seb derm is such a common condition, but like me, many people may have a hard time trying to figure out what it is and what can be do